Article
Dermatology
Mariko Ogawa-Momohara, Yoshinao Muro, Chiaki Murase, Tomoki Taki, Kana Tanahashi, Yuta Yamashita, Haruka Koizumi, Ryo Fukaura, Takuya Takeichi, Masashi Akiyama
Summary: This small-scale prospective study investigated the changes in antigen-specific IgG4 (sIgG4) during long-term dupilumab treatment in patients with atopic dermatitis. Despite the reported inhibitory effect of dupilumab on B-cell maturation, the increase in sIgG4 during the treatment suggests a potential indirect improvement of allergies in predisposed individuals. This study presents the possibility of a new therapeutic effect of long-term dupilumab use.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaci, Carle Paul, Andrew E. Pink, Yoko Kataoka, Chia-Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernan Valdez
Summary: The study demonstrated that both 200 mg and 100 mg doses of abrocitinib showed significant efficacy in treating moderate-to-severe atopic dermatitis compared to placebo, with the 200 mg dose being superior to dupilumab in improving itch response. Neither dose of abrocitinib showed significant differences from dupilumab in most other key secondary endpoints at week 16.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Dermatology
Masako Matsutani, Yasutomo Imai, Yukako Inoue, Minori Nakatani-Kusakabe, Masaru Natsuaki, Kiyofumi Yamanishi, Nobuo Kanazawa
Summary: The combination therapy of tacrolimus ointment and dupilumab for treating facial AD showed to be safe and effective in a study of 109 patients, with no serious side effects observed and significant improvement in dermatitis. The correlation between improvement in facial and systemic dermatitis scores indicates the overall efficacy of the combination treatment.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Andac Salman, Ozlem Apti Sengun, Meryem Aktas, Oktay Taskapan
Summary: The study found high effectiveness and safety of dupilumab in treating moderate-to-severe AD in real-life conditions, with most patients continuing treatment during the COVID-19 pandemic without adverse outcomes. Although the rate of conjunctivitis was higher than in clinical trials, no patients discontinued treatment due to adverse effects.
DERMATOLOGIC THERAPY
(2022)
Article
Medicine, General & Internal
Federica Gelato, Luca Mastorino, Ekaterina Stepkina, Giovanni Cavaliere, Simone Ribero, Pietro Quaglino, Michela Ortoncelli
Summary: This retrospective study compares the efficacy of dupilumab therapy in patients with intrinsic and extrinsic atopic dermatitis (AD) and finds no significant differences in treatment outcome between the two groups, suggesting that dupilumab is equally effective regardless of IgE levels.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Allergy
Esme Kamphuis, Celeste M. Boesjes, Laura Loman, Daphne S. Bakker, Mila Poelhekken, Nicolaas P. A. Zuithoff, Marijke Kamsteeg, Geertruida L. E. Romeijn, Femke van Wijk, Marjolein S. de Bruin-Weller, Marlies de Graaf, Marie L. A. Schuttelaar
Summary: This study evaluated the effectiveness and safety of 28 weeks dupilumab treatment on pediatric patients with moderate-to-severe AD in daily practice. The results showed significant improvement in disease severity, symptoms, and serum biomarkers, with common side effects of conjunctivitis and headache. The predicted-EASI had a significant correlation with disease severity.
PEDIATRIC ALLERGY AND IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, H. Chih-ho Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez, Urs Kerkmann
Summary: This study compared the efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis. Results showed that abrocitinib was more effective in inducing early reductions of itch and atopic dermatitis disease signs under background topical therapy.
Article
Dermatology
Cataldo Patruno, Gabriella Fabbrocini, Giuseppe Longo, Giuseppe Argenziano, Silvia Mariel Ferrucci, Luca Stingeni, Ketty Peris, Michela Ortoncelli, Annamaria Offidani, Giuseppe Fabrizio Amoruso, Marina Talamonti, Giampiero Girolomoni, Teresa Grieco, Michela Iannone, Eustachio Nettis, Caterina Foti, Franco Rongioletti, Monica Corazza, Michele Delli Veneri, Maddalena Napolitano
Summary: The study evaluated the efficacy and safety of Dupilumab in treating elderly patients with atopic dermatitis over 52 weeks. Results showed a reduction in disease severity scores and a low rate of adverse events, indicating that Dupilumab is an effective and safe long-term treatment option for atopic dermatitis in patients aged over 65 years.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2021)
Article
Allergy
Julian Londono, Lucia Perez, Sergio Moreno, Edgardo Chapman, Maria Beatriz Garcia, Ana Maria Celis, Maria Angelica Munoz, David Castillo, Jorge Sanchez, Yaicith Arevalo, Ana Lozano, Nelson J. Alvis-Zakzuk, Cesar Munoz, Laura Botero, Catalina Beltran, Elizabeth Garcia
Summary: This study describes the effectiveness and safety of Dupilumab as a treatment for moderate to severe atopic dermatitis in a Colombian multicenter cohort. The results show that Dupilumab is effective and safe in real-life clinical settings.
WORLD ALLERGY ORGANIZATION JOURNAL
(2023)
Article
Dermatology
A. Lasek, N. Bellon, S. Mallet, E. Puzenat, A. C. Bursztejn, C. Abasq, J. Mazereeuw-Hautier, C. Chiaverini, T. Hubiche, N. Raison Peyron, A. Du Thanh, S. Barbarot, H. Aubert, Z. Reguiai, C. Droitcourt, C. Fievet, A. Bellissen, M. Bachelerie, A. Nosbaum, A. Leymarie, P. Armingaud, M. Masson Regnault, E. Mahe
Summary: This study evaluated the effectiveness and safety of Dupilumab in the daily practice of children aged 6-11 with moderate-to-severe atopic dermatitis (AD). The results showed a significant decrease in disease severity scores after 3 months of treatment, as well as a lower frequency of adverse events compared to previous trials. However, the administration of injectable form may present challenges in this age group. Overall, Dupilumab is an effective and safe treatment option for children with moderate-to-severe AD.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Biology
Angela Ayen-Rodriguez, Jose-Juan Pereyra-Rodriguez, Francisco J. Navarro-Trivino, Sara Alcantara-Luna, Javier Dominguez-Cruz, Manuel Galan-Gutierrez, Samuel Vilar-Palomo, Jose Carlos Armario-Hita, Ricardo Ruiz-Villaverde
Summary: This study reviewed clinical trials of biological drugs for the treatment of moderate and severe atopic dermatitis. The study found that Upadacitinib had the best improvement in Eczema Area and Severity Index (EASI 75), and adding TCS further improved its efficacy. This study is important for the development of management guidelines for new generation therapies for atopic dermatitis.
Article
Medicine, General & Internal
Bingjing Zhou, Cong Peng, Liqiao Li, Runqiu Liu, Lei Zhu, Xiang Chen, Jie Li
Summary: This study collected and analyzed real-world data on the use of dupilumab among 116 Chinese patients with atopic dermatitis. The results showed significant improvements in disease symptoms and quality of life in patients treated with dupilumab over 16 weeks, with a low incidence of adverse events.
FRONTIERS IN MEDICINE
(2022)
Review
Biology
George G. Mitroi, Loredana Elena Stoica, George F. Mitroi, Mihaela Roxana Mitroi, Cristina Violeta Tutunaru, Oana Maria Ica, Laura Simona Ianosi
Summary: Dupilumab is currently the only available biological treatment for moderate-to-severe atopic dermatitis, but limited clinical data on its safety profile are available, and its interactions with other drugs and adverse effects on patients with multiple comorbidities are not yet known.
Article
Dermatology
M. C. Fargnoli, M. Esposito, S. Ferrucci, G. Girolomoni, A. Offidani, A. Patrizi, K. Peris, A. Costanzo, G. Malara, G. Pellacani, M. Romanelli, P. Amerio, A. Cristaudo, M. L. Flori, A. Motolese, P. Betto, C. Patruno, P. Pigatto, R. Sirna, G. Stinco, I. Zalaudek, L. Bianchi, V. Boccaletti, S. P. Cannavo, F. Cusano, S. Lembo, R. Mozzillo, R. Gallo, C. Potenza, F. Rongioletti, R. Tiberio, T. Grieco, G. Micali, S. Persechino, M. Pettinato, S. Pucci, E. Savi, L. Stingeni, A. Romano, G. Argenziano, Giulia Calabrese, Anna Campanati, Cristiano Caruso, Camilla Chello, Tiziana De Pasquale, Luisa Di Costanzo, Valentina Dini, Rocco De Pasquale, Micol Del Giglio, Giovanna Fracassi, Niccolo Gori, Domenico Giordano, Alessandro Giunta, Carlotta Gurioli, Katharina Hansel, Agostina Legori, Camilla Loi, Giuseppe Matteo Maini, Ilenia Marafioti, Giovanna Meogrossi, Katiuscia Nan, Maddalena Napolitano, Diego Orsini, Maria Parodi, Camilla Peccianti, Cristina Pellegrini, Viviana Piras, Annunziata Raimondo, Filomena Russo, Marina Talamonti, Simona Tavecchio, Caterina Trifiro, Mario Valenti, Federica Veronese, Martina Vispi, Yiran Wei
Summary: A retrospective cohort study conducted in Italy showed that dupilumab significantly improved disease symptoms in adults with moderate-to-severe atopic dermatitis, including itch and sleep loss, with an acceptable safety profile.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2021)
Article
Dermatology
Ying Li, Jiajing Lu, Rongfen Chen, Yu Wang, Yangfeng Ding, Shuang Xu, Ying Zou, Xuemei Yi, Yuling Shi
Summary: This retrospective study evaluated the efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in China. The results showed that most patients achieved EASI-50 and EASI-75 after 12 weeks of treatment. Adverse events were minimal, with conjunctivitis, injection site reactions, and herpes simplex virus infections being the most common. Additionally, there were significant decreases in circulating eosinophil counts and total IgE concentrations.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Tessa A. Kouwenhoven, Jeroen A. M. van Der Ploeg, Peter C. M. van de Kerkhof
JOURNAL OF DERMATOLOGICAL TREATMENT
(2020)
Letter
Dermatology
A. N. Voorberg, W. F. A. den Dunnen, R. H. J. Wijdh, M. S. de Bruin-Weller, M. L. A. Schuttelaar
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2020)
Article
Allergy
Lieneke F. M. Ariens, Jorien van der Schaft, Daphne S. Bakker, Deepak Balak, Margreet L. E. Romeijn, Tessa Kouwenhoven, Marijke Kamsteeg, Barbara Giovannone, Julia Drylewicz, Cynthia Catalina Aurora van Amerongen, Evelien M. Delemarre, Edward F. Knol, Femke van Wijk, Stefan Nierkens, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein S. de Bruin-Weller
Article
Dermatology
Angelique N. Voorberg, Hanna Niehues, Jart A. F. Oosterhaven, Geertruida L. E. Romeijn, Ivonne M. J. J. Vlijmen-Willems, Piet E. J. Erp, Thomas H. A. Ederveen, Patrick L. J. M. Zeeuwen, Marie L. A. Schuttelaar
Summary: Hand eczema is a common inflammatory skin condition of the hands with unknown pathogenesis. Through RNA-sequencing analysis, this study found significantly elevated expression of genes/proteins related to keratinocyte host defense and inflammation in lesional skin of patients with vesicular hand eczema.
EXPERIMENTAL DERMATOLOGY
(2021)
Article
Dermatology
Jart A. F. Oosterhaven, Lotte S. Spekhorst, Junfen Zhang, Angelique N. Voorberg, Geertruida L. E. Romeijn, Celeste M. Boesjes, Marlies de Graaf, Marjolein S. de Bruin-Weller, Marie L. A. Schuttelaar
Summary: The study found that AD patients treated with dupilumab had high treatment satisfaction, but there may be challenges in interpreting eczema control based on the ADCT.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Letter
Dermatology
J. Zhang, L. Loman, A. N. Voorberg, M. L. A. Schuttelaar
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Roselie E. Achten, Chantal Van Luijk, Lisa Van der Rijst, Daphne Bakker, Lotte Spekhorst, Nicolaas Zuithoff, Marie Schuttelaar, Geertruida Romeijn, Angelique Voorberg, Marijke Kamsteeg, Inge Haeck, Marlies De Graaf, Judith Thijs, Joke De Boer, Marjolein De Bruin-Weller
Summary: Patients with a history of any eye disease and the use of ophthalmic medication at baseline were more likely to develop dupilumab-associated ocular surface disease.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Dermatology
Angelique N. Voorberg, Laura Loman, Marie L. A. Schuttelaar
Summary: There is limited data on chronic hand eczema and its severity in the general population. This cross-sectional study investigated the prevalence and severity of hand eczema in the Dutch population through a questionnaire. The results showed that the lifetime prevalence of hand eczema was 15.0%, the 1-year prevalence was 7.3%, and the self-reported physician-diagnosed prevalence was 6.1%. The study also found that the majority of subjects with hand eczema had almost clear symptoms at their worst, and the prevalence of severe to very severe hand eczema in the general population was 1.9%. The study suggests that future epidemiological research should include data on chronic hand eczema and its severity to gain a better understanding of the burden of hand eczema.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Allergy
Jacob P. Thyssen, Marie L. A. Schuttelaar, Jose H. Alfonso, Klaus E. Andersen, Irena Angelova-Fischer, Bernd W. M. Arents, Andrea Bauer, Richard Brans, Alicia Cannavo, Wianda A. Christoffers, Marie-Noelle Crepy, Peter Elsner, Manige Fartasch, Francesca Larese Filon, Ana M. Gimenez-Arnau, Margarida Goncalo, Maria G. Guzman-Perera, Carsten R. Hamann, Wolfram Hoetzenecker, Jeanne Duus Johansen, Swen M. John, Amalia C. M. Kunkeler, Suzana Ljubojevic Hadzavdic, Sonja Molin, Rosemary Nixon, Jart A. F. Oosterhaven, Thomas Rustemeyer, Esther Serra-Baldrich, Mili Shah, Dagmar Simon, Christoph Skudlik, Radoslaw Spiewak, Skaidra Valiukeviciene, Angelique N. Voorberg, Elke Weisshaar, Tove Agner
Summary: Hand eczema is a common inflammatory skin disorder. This article aims to update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment of hand eczema. Consensus was reached for several statements and management strategies through analysis of evidence for therapeutic and preventive interventions using a structured method of developing consensus. The updated guideline should improve the management of hand eczema.
CONTACT DERMATITIS
(2022)
Editorial Material
Allergy
Angelique N. Voorberg, Esme Kamphuis, Wietske A. Christoffers, Geertruida L. E. Romeijn, Jart A. F. Oosterhaven, Marie L. A. Schuttelaar
CONTACT DERMATITIS
(2022)
Article
Allergy
Angelique N. Voorberg, Geertruida L. E. Romeijn, Marjolein S. de Bruin-Weller, Marie L. A. Schuttelaar
Summary: This study suggests that Dupilumab may be a suitable treatment option for isolated CHE, with long-term therapeutic effects on HE patients.
CONTACT DERMATITIS
(2022)
Article
Allergy
Fieke M. Rosenberg, Rene Wardenaar, Angelique N. Voorberg, Diana C. J. Spierings, Marie-Louise A. Schuttelaar
Summary: This study re-analyzed the transcriptome data of vesicular hand eczema (VHE) and atopic dermatitis (AD), and found that interferon signaling and necroptosis were significantly increased in VHE compared to AD, as well as some downregulated genes unique to VHE.
CONTACT DERMATITIS
(2023)
Article
Dermatology
Tessa A. Kouwenhoven, Peter C. M. van de Kerkhof, Marijke Kamsteeg
ACTA DERMATO-VENEREOLOGICA
(2019)
